Life sciences company specializing on psychedelics therapies for mental illness patients Lobe Life Sciences Ltd. (CSE: LOBE) (OTC: GTSIF) announced having submitted application for key Patent Cooperation Treaty (PCT) titled ‘Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder.’
A PCT is an international patent law treaty which highlights procedures for filing patent application to protect inventions in each of its member state.
When a company files for one international patent under the PCT it simultaneously seeks invention protection across of the 153 member states.
This PCT filing captures details that were previously submitted in three separate provisional patent applications with the United States Patent and Trademark Office (UPTSO).
The PCT relates to methods used in treating or alleviating symptoms of mild traumatic brain injury (mTBI), post-traumatic stress disorder (PTSD) and a combination of both through administration of a psychedelic substance together with N-acetylcysteine (NAC).
The company’s chief executive Philip Young said it is important to protect their innovations as they move forward and continue to work on new ones as a company.
“We are committed to pursuing patent protection for our inventions as we continue with our development initiatives. It is important that our intellectual property is safeguarded as we continue on our path to drug and device development, and prepare for our clinical trials,” said the CEO.
